CClinicalTrials.gg
TerminatedNCT04920630Updated Aug 23, 2023

TRAIN Your Sleep; Treating Adolescent Insomnia With Cognitive Behavioral Therapy for Insomnia (CBT-I)

An interventional study of Cognitive Behavioral Therapy - Insomnia (CBT-I) in Insomnia and Chronic Pain, sponsored by Indiana University. Terminated at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-08-23.

Sponsored by Indiana University · Not applicable, Interventional, and Health services research

Why this study was terminated
Research team members no longer employed. Determination made to utilize pilot data already obtained and close study to enrollment.
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The primary aim of this study is to understand how insomnia contributes to chronic pain in youth. Specifically, the investigators are interested in how insomnia and the treatment of insomnia impact emotional states and the body's ability to efficiently modulate pain, either to increase or decrease pain perception. It is hypothesized that insomnia is associated with increased negative emotional states and impaired pain modulation, which will improve after treatment of insomnia. In this project, the objectives are to 1) evaluate the role of pain modulation as a potential mechanism through which insomnia impacts pain symptoms, and 2) evaluate the role of negative affect as mediators of the impact of insomnia on pain modulation.

Study participation will consist of a baseline assessment, a 5 session (once per week) virtual group cognitive behavioral therapy for insomnia (CBT-I) intervention, and a follow-up assessment. Investigators will also ask teen participants to complete the consensus sleep diary daily for 7 days prior to the baseline and follow up study visits. Assessment visits will consist of two types of assessments, questionnaires and quantitative sensory testing (QST). Participating parents and teens will complete questionnaires (both child and parent report) assessing the child's pain, sleep, and psycho-social variables. QST will assess pain inhibition via conditioned pain modulation (CPM) and pain facilitation via temporal summation (TS).

02

Conditions studied

03

In context

Sleep Initiation and Maintenance Disorders

1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.

This study's enrollment of 26 is below the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Indiana University is the lead sponsor of 958 studies on the registry; 200 are open to participants now.

Of its 142 completed or terminated interventional studies of FDA-regulated products, 112 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Youth Inclusion Criteria:

  • Aged 12 to 17 years.
  • Meets criteria for insomnia with or without comorbid chronic musculoskeletal pain.
  • Parent/guardian available to provide consent.
  • Patient and a primary caregiver are able to independently read and understand English well enough to provide informed consent and complete study procedures.
  • Access to email, internet, and audio and video call capabilities.

Parent/Guardian Inclusion Criteria:

  • Parent/legal guardian of a child meeting above eligibility criteria
  • Able to independently read and understand English well enough to provide informed consent and complete study questionnaires.

Youth Exclusion Criteria:

  • History of cardiac or neuromuscular disorder
  • Parent-report of child's use of Opioid medications (i.e., fentanyl, morphine, hydromorphone, methadone, hydrocodone, oxycodone) that cannot be discontinued for 7 days prior to study visits.
  • Inadequate proficiency in English or a developmental disability that interferes with informed consent/assent or completion of study procedures.
  • History of obstructive sleep apnea, restless leg syndrome, or narcolepsy.
  • History of bipolar disorder and/or manic episodes
  • Diagnosis of epilepsy.
  • Currently in foster care or considered a ward of the state.
  • History of Raynaud Syndrome.
  • Active suicidal ideation, intent or plan in the past month.

Parent Exclusion Criteria:

  • Inadequate proficiency in English or a developmental disability that interferes with informed consent or completion of questionnaires.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    CBT-I

    5-weekly Cognitive Behavioral Therapy for Insomnia group therapy sessions conducted virtually.

    Behavioral: Cognitive Behavioral Therapy - Insomnia (CBT-I)

Interventions

  • BehavioralCognitive Behavioral Therapy - Insomnia (CBT-I)

    CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.

    Also known as: CBT-I

06

What researchers measure

Primary outcomes

  1. Change from baseline Conditioned Pain Modulation (CPM)

    Heat pain threshold (test stimulus) will be assessed on the volar surface of the dominant forearm twice before before, during, and after immersion (for 1 minute) of the non-dominant hand in a circulated cold-water bath (conditioning stimulus) maintained at 5˚C ±1˚C. Heat pain threshold will be assessed via the method of limits. Subjects will be instructed to push a button as soon as the heat feels painful, which will stop the trial. Immediately before and after the CPM assessment, the subjects' non-dominant hand will be placed in a room-temperature water bath (20-25˚C) for 2 minutes. The CPM effect will be calculated as a difference score: heat pain threshold during conditioning stimulus minus baseline. A negative score indicates pain inhibition.

    Time frame: 1-4 weeks post-treatment

  2. Change from baseline Temporal Summation of Pain (TS)

    Temporal summation will be assessed via a series of 10 brief (\~0.5s duration for peak, total time for heating, peak, and cooling \<1.5s) heat pulses (48˚C) delivered via a Medoc Thermal Sensory Analyzer-2 thermode positioned on the volar surface of the forearm. Time between each peak will be 3 seconds. Subjects will provide a verbal pain rating immediately after the first and last heat pulse is delivered. Pain ratings will be made on a 0-100 numerical rating scale (0=no pain, 100=most pain imaginable), which will be displayed during the assessment. Temporal summation will be calculated as a difference score (i.e., pain during final stimulus minus pain during initial stimulus), with a positive score indicating pain facilitation due to temporal summation.

    Time frame: 1-4 weeks post-treatment

Secondary outcomes

  1. Change from baseline score on Generalized Anxiety Disorder -7

    Generalized Anxiety Disorder - 7 (GAD-7). The GAD-7 is a 7 item screener for anxiety focused on symptoms of anxiety over the past week. Each item is scores on a 0-3 scale and summed to create a total score that ranges from 0-21.

    Time frame: 1-4 weeks post-treatment

  2. Change from baseline score on Patient Health Questionnaire - 9 Adolescent Form (PHQ9-A).

    The PHQ9-A is a validated 9 item self-report scale (4-point Likert scale) assessing symptoms of depression. Scores range from 0-27 with 0-4 indicating no or minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression.

    Time frame: 1-4 weeks post-treatment

  3. Change from Baseline Score on Positive and Negative Affect Schedule (PANAS)

    he PANAS is a 20-item self- and parent-report measure assessing positive and negative affect. Responses are made on a 5-point Likert scale. A separate score is calculated for negative (10 items) and positive (10 items) affect and higher scores reflect higher levels of experienced affect.

    Time frame: 1-4 weeks post-treatment

  4. Change from baseline score on Pediatric Insomnia Severity Index (PISI)

    The PISI is a 6-item parent- and child-report scale measuring insomnia severity. Total scores range from 0-30 with higher scores reflecting greater insomnia severity.

    Time frame: 1-4 weeks post-treatment

07

Study locations

1 site
  • Riley Hospital for Childre
    Indianapolis, Indiana 46202, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04920630
Lead sponsor
Indiana University
Collaborators
Indiana Clinical and Translational Sciences Institute
Responsible party
Amy E. Williams (Associate Professor of Clinical Psychiatry, Indiana University) — Principal investigator
First posted
Jun 10, 2021
Start date
May 10, 2021
Primary completion
May 5, 2023
Completion
May 5, 2023
Last update
Aug 23, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion